

14 June - 21 June

COMPANY SPOTLIGHT

- **Biodesix, Inc.** (Broomfield) announced that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy..
- **Accelr8 Technology Corporation** (Denver) announced that it signed a technology evaluation agreement for its BACcel™ rapid diagnostic system with a global diagnostics company. The short-term agreement includes an option for a license to complete product development, obtain regulatory approvals, and produce and market innovative diagnostic products based on the technology in global markets. The agreement calls for an initial payment plus scheduled payments of additional funds until completion of data evaluation.

The company also released results from its presentation at the annual General Meeting of the American Society for Microbiology (ASM) in San Diego on May 24. The study addressed the three major species that cause about half of serious hospital-acquired infections (HAI) and are prone to acquire multiple mechanisms of antibiotic resistance. The 2-hour test, directly from specimen, achieved quantitative accuracy equal to that of the standard culture reference method. Identification sensitivity and specificity ranged from 90% to 100% with different organisms.

- **CaridianBCT** (Lakewood) announced that the Japanese Red Cross considers the Mirasol Pathogen Reduction Technology System for platelets stored in plasma the best available technology for Japanese needs. The decision was announced via a report that compared the CaridianBCT Mirasol to other pathogen reduction technologies.
- **Allos Therapeutics, Inc.** (Westminster) announced that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). Allos is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL. In addition, the Company plans to conduct a Phase 3 clinical study comparing FOLOTYN in combination with systemic bexarotene versus systemic bexarotene alone in patients with CTCL who are refractory to at least one prior systemic therapy.

- **Vitro Diagnostics, Inc.** (Golden) , and **HemoGenix®, Inc.** (Colorado Springs) announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting held in San Francisco last week. The new products extend the well established HALO® assay platform for hematopoietic stem cells to now include mesenchymal stem cells and induced pluripotent stem cells (iPS) as well. These new high performance assays provide an ability to analyze stem cells for determination of quality, potency and response to toxic agents.

SQUARE PEGS

- The application for the therapeutic tax credit has just been released. The forms and instructions are attached, as well as a summary of key elements of the application, provided by CBSA corporate sponsor Polsinelli Shughart PC. Please contact CBSA for a referral to all partners available to assist with the application.
- CBSA Board Chair, Rick Jory, President and CEO of **Sandhill Scientific, Inc.**, was recognized by the Denver Business Journal as finalist for 2010 Entrepreneur of the Year. [Click here to read more.](#)
- **The Medical Career Collaborative (MC2)** program at **The Children's Hospital** provides high school students from disadvantaged socio-economic backgrounds an opportunity to gain experience and exposure in the fields of health, medicine and bioscience. This two year program includes a paid internship at Children's and help with college preparation. Over the last ten years, 200 students have enrolled in MC2 and all have graduated from high school. The program is currently seeking cosponsors from the bioscience community. Please see the attached document for more information.

UPCOMING EVENTS

- BioMARC, the regional training center for product translation at Colorado State University, will be holding a lunch-and-learn short course sponsored by GE Healthcare on Tuesday, June 29, on "Applying Filtration, WAVE Reactor, and Chromatography Single-Use Technologies to BioProcessing". [Click here for more info or to register.](#)
- On Monday July 12, from noon to 5pm, Congresswoman Betsy Markey will hold an Innovation Summit. The event will be held in conjunction with the City of Fort Collins and Colorado State University. The keynote speaker will be John R. Fernandez, the Assistant Secretary for Economic Development and the U.S. Department of Commerce. The meeting will take place in the Main Ballroom of the Lory Student Center, with networking at Odell Brewing Company immediately

following. The event is free but RSVP is required. Please respond to Jamie Grim at jamie.grim@mail.house.gov or 970-221-7110.

- An informal meeting to discuss Bioscience Education will be held on July 14 from 1:30 to 3:30 pm in the Amgen Room of the Bioscience Center at Fitzsimons. The aims of the meeting are information sharing, programmatic awareness, and discussing collaborative planning for resource sharing, fund raising, and potentials for development of industry linkages and multipurpose training sites. Please RSVP to Jerry McCarthy at fairhill@gmail.com or call 303-229-0957.

- Colorado State University's BioMARC Outreach Training Program for Product Translation will host a workshops on Clinical Trial Management, FDA Requirements, & GCP in the Amgen Conference Room Bioscience Park Center at Fitzsimons on [July 22](#) and [July 23](#). The second session on July 23 will focus on medical devices.

SAVE THE DATE: Please join us for the **Roche Colorado Corporation** Peptide Symposium (RCCPS) on September 14 – 16, 2010 at the St. Julian Hotel and Spa in Boulder, CO. The program highlights include; Peptides in the Clinic; Peptide Drug Delivery; Emerging Technologies; Advances in Peptide Chemistry; and, Quality by Design in Peptides. The following link www.rccps.org, and attachments will provide additional information on the conference and sponsorship opportunities. We look forward to showcasing Colorado as a leader in Peptides at this conference and hope you will be able to join us! Please see attached flyer for information on sponsorship opportunities.